Welcome to the e-CCO Library Archive!

Filter:
P587

Tacrolimus suppositories in therapy-resistant ulcerative proctitis - a single center experience

Authors:

S. Jaeger*1, K. Hoeger1, J. Wehkamp2, E. Stange1, M. Escher1

1Robert Bosch Krankenhaus, Gastroenterology, Stuttgart, Germany, 2University of Tuebingen, Gastroenterology, Tuebingen, Germany

P588.

The prevalence and risk factors of low bone mineral density in a Slovak IBD cohort

Authors:

A. Krajcovicova, T. Hlavaty, Z. Killinger, E. Miznerova, J. Toth, D. Cierny, T. Koller, J. Letkovsky, Z. Zelinkova, M. Huorka, J. Payer, University Hospital Bratislava, 5th Department of Internal Medicine, Bratislava, Slovakia

P588. A randomized double blind placebo controlled trial to assess the efficacy of a probiotic preparation as maintenance therapy in patients with ulcerative colitis
Authors:

Y. Suzuki1, A. Yamada1, Y. Yoshimatsu1, K. Takeuchi1, 1Sakura Medical Center, Toho University, Internal Medicine, Sakura city, Japan

P588

A prospective evaluation of adalimumab drug levels and anti-drug antibodies using two commercial ELISA and the influence of 6-thioguanine nucleotides amongst patients with Crohn's disease

Authors:

M. Ward*1, 2, B. Warner2, S.W. Chuah3, 4, S. Shieh3, N. Unsworth5, J. Sanderson2, M. Parkes3, Z. Arkir5, P. Irving2

1Alfred Hospital, Gastroenterology, Melbourne, Australia, 2Guy’s and St. Thomas Hospital, Gastroenterology, London, United Kingdom, 3The Queen Elizabeth Hospital NHS Trust & Addenbrookes Hospital, Gastroenterology, King's Lynn & Cambridge, United Kingdom, 4Singapore General Hospital, Department of Internal Medicine, Singapore, Singapore, 5Guy’s and St. Thomas Hospital, Reference Chemistry, Viapath, London, United Kingdom

P589.

The future of academic gastroenterology – insights from a Europe-wide survey of trainees

Authors:

J. Lee1, M. Duijvestein2, G. Pellino3, F. Rieder4, F. Scaldaferri5, S. Zeissig6, P. Hindryckx7, T. Raine1, S. Vermeire8, 1University of Cambridge, Department of Medicine, Cambridge, United Kingdom, 2Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands, 3Second University of Naples, Department of Surgery, Naples, Italy, 4Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, United States, 5Catholic University of Rome, Department of Internal Medicine, Rome, Italy, 6University Medical Center Schleswig-Holstein, Department of Internal Medicine, Kiel, Germany, 7Ghent University, Department of Gastroenterology, Gent, Belgium, 8Catholic University of Leuven, Department of Internal Medicine and Endoscopy, Leuven, Belgium

P589. A qualitative exploration of the follow up needs of patients with inflammatory bowel disease
Authors:

K. Kemp1, J. Griffiths2, S. Campbell3, K. Lovell2, 1University of Manchester / Manchester Royal Infirmary, School of Nursing / Gastroenterology, Manchester, United Kingdom, 2University of Manchester, School of Nursing, Manchester, United Kingdom, 3Manchester Royal Infirmary, Gastroenterology, Manchester, United Kingdom

P589

Change in clinical features of Korean Crohn's Disease patients following the introduction of an anti-TNF-alpha agent: Results from the CONNECT study

Authors:

Y.S. Kim*1, S.I. Bae1, B.D. Ye2, J.P. Im3, J.W. Kim3, J.S. Kim3, J.H. Cheon4, Y.-H. Kim5, D.S. Han6, W.H. Kim4, C.H. Yang7

1Inje University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 2University of Ulsan College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 3Seoul National University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 4Yonsei University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 5Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, Korea, Republic of, 6Hanyang University Guri Hospital, Gastroenterology, Guri, Korea, Republic of

,

7Dongguk University College of Medicine Gyeongju Hospital, Division of Gastroenterology & Hepatology, Department of Internal Medicine, Gyeongju, Korea

P590.

The features of IBD in young patients – evaluation of a batch of more than 1,000 patients

Authors:

A. Goldis1, D. Dobru2, L. Gheorghe3, C. Gheorghe3, C. Chijevschi4, M. Tantau5, G. Constantinescu3, I. Ratiu1, D. Lazar1, R. Iacob3, M. Diculescu3, on behalf of the IBDPROSPECT Study Group, 1University of Medicine Timisoara, Gastroenterology, Timisoara, Romania, 2University of Medicine Targu Mures, Gastroenterology, Targu Mures, Romania, 3University of Medicine Bucharest, Gastroenterology, Bucharest, Romania, 4University of Medicine Iasi, Gastroenterology, Iasi, Romania, 5University of Medicine Cluj-Napoca, Gastroenterology, Cluj-Napoca, Romania

P590. Allogeneic mesenchymal stromal cells for biologic refractory luminal Crohn's disease
Authors:

G. Forbes1, M. Sturm1, R. Leong2, M. Sparrow3, D. Segarajasingam4, A. Cummins5, R. Herrmann1, 1Royal Perth Hospital, Perth, Australia, 2Concord Hospital, Sydney, Australia, 3The Alfred Hospital, Melbourne, Australia, 4Sir Charles Gairdner Hospital, Perth, Australia, 5The Queen Elizabeth Hospital, Adelaide, Australia

P590

Inflammatory Bowel Disease Patient's Participation in Therapeutic Decision Making

Authors:

S. Vavricka1, G. Rogler1, E. Safroneeva2, A. Schoepfer*3

1University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 3Centre Hospitalier Universitaire Vaudois, Gastroenterology and Hepatology, Lausanne, Switzerland

P591.

The clinical features and prognosis of Crohn's disease: A Korean multicenter nationwide cohort study

Authors:

B.D. Ye1, D.S. Han2, E.J. Youn1, J.H. Lee3, J.H. Cheon4, H.-S. Kim5, H.-S. Kim6, Y.-H. Kim7, Y.S. Kim8, S.-A. Jung9, K.-M. Lee10, C.K. Lee11, S.J. Park4, G.S. Seo12, J.S. Kim13, J.P. Im13, C.H. Choi14, D.I. Park7, B.I. Jang15, J.M. Cha11, K.C. Huh16, J.W. Kim17, H.J. Song18, Y.S. Park19, H.J. Jang20, S.H. Jung21, S.W. Jung22, G.H. Baik23, J.S. Koo24, J.-O. Kim25, T.O. Kim26, G.A. Song27, Y.E. Joo5, S.J. Shin28, S.M. Yoon29, Y.T. Jeen30, S.-K. Yang1, H.J. Kim11, W.H. Kim4, 1University of Ulsan College of Medicine, Asan Medical Center, Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea, Republic of, 2Hanyang University Guri Hospital, Hanyang University College of Medicine, Internal Medicine, Guri, Korea, Republic of, 3Seoul Song Do Colorectal Hospital, Digestive Endoscopic Center, Seoul, Korea, Republic of, 4Yonsei University College of Medicine, Internal Medicine and Institute of Gastroenterology, Seoul, Korea, Republic of, 5Chonnam National University Medical School, Internal Medicine, Gwangju, Korea, Republic of, 6Yonsei University Wonju College of Medicine, Internal Medicine, Wonju, Korea, Republic of, 7Sungkyunkwan University School of Medicine, Medicine, Seoul, Korea, Republic of, 8Seoul Paik Hospital, Inje University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 9Ewha Womans University School of Medicine, Internal Medicine, Seoul, Korea, Republic of, 10St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Internal Medicine, Suwon, Korea, Republic of, 11Kyung Hee University School of Medicine, Internal Medicine, Seoul, Korea, Republic of, 12Wonkwang University College of Medicine, Internal Medicine, Digestive Disease Research Institute, Iksan, Korea, Republic of, 13Seoul National University College of Medicine, Internal Medicine and Liver Research Institute, Seoul, Korea, Republic of, 14Chung-Ang University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 15Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea, Republic of, 16Konyang University College of Medicine, Internal Medicine, Daejeon, Korea, Republic of, 17Seoul National University Boramae Hospital, Internal Medicine, Seoul, Korea, Republic of, 18Jeju National University School of Medicine, Internal Medicine, Jeju, Korea, Republic of, 19Eulji University School of Medicine, Internal Medicine, Seoul, Korea, Republic of, 20Hallym University College of Medicine, Internal Medicine, Hwaseong, Korea, Republic of, 21Eulji University School of Medicine, Internal Medicine, Daejeon, Korea, Republic of, 22University of Ulsan College of Medicine, Ulsan University Hospital, Internal Medicine, Ulsan, Korea, Republic of, 23Hallym University College of Medicine, Internal Medicine, Chuncheon, Korea, Republic of, 24Korea University College of Medicine, Internal Medicine, Ansan, Korea, Republic of, 25Soonchunhyang University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 26Haeundae Paik Hospital, Inje University College of Medicine, Internal Medicine, Busan, Korea, Republic of, 27Pusan National University School of Medicine, Internal Medicine, Busan, Korea, Republic of, 28Ajou University School of Medicine, Gastroenterology, Suwon, Korea, Republic of, 29Chungbuk National University College of Medicine, Internal Medicine, Cheongju, Korea, Republic of, 30Korea University College of Medicine, Internal Medicine, Seoul, Korea, Republic of

P591. A prospective controlled pilot study of faecal microbiota transplantation for chronic refractory pouchitis
Authors:

J. Landy1, H. Omar Al-Hassi2, E. Ronde2, E. Mann2, S. Peake1, S. McLaughlin3, Z.L. Perry-Woodford4, P.J. Ciclitira5, R.J. Nicholls6, S.K. Clark7, S. Knight2, A.L. Hart1, 1St Mark's Hospital, IBD Unit, London, United Kingdom, 2Antigen Presentation Research Group, Imperial College, London, United Kingdom, 3Royal Bournemouth and Christchurch NHS Hospitals Trust, Gastroenterology, Bournemouth, United Kingdom, 4St Mark's Hospital, London, United Kingdom, 5St Thomas' Hospital, Gastroenterology, London, United Kingdom, 6Imperial College, Department of Biosurgery and Surgical Technology, London, United Kingdom, 7St Mark's Hospital, Colorectal Surgery, London, United Kingdom

P591

The effect of Infliximab therapy on the Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Inflammatory Bowel Disease patients

Authors:

E. Stefanidis1, P. Katsinelos1, N. Papanikolaou2, K. Anastasiadou1, J. Kountouras*1

1Aristotle University of Thessaloniki, Second Medical Clinic, Ippokration Hospital, Thessaloniki, Greece, 2Aristotle University of Thessaloniki, Department of Biochemistry, Medical School, Thessaloniki, Greece

P592.

The characteristics of pediatric inflammatory bowel disease in Korea: comparison to EUROKIDS data

Authors:

D.I. Park1, S.Y. Choi1, E.R. Kim2, Y.H. Kim2, C.K. Lee3, K.C. Huh4, K.M. Lee5, 1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Internal medicine, Seoul, South Korea, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Medicine, Seoul, South Korea, 3Kyung Hee University School of Medicine, Internal medicine, Seoul, South Korea, 4Konyang University College of Medicine, Internal medicine, Daejeon, South Korea, 5St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Internal medicine, Suwon, South Korea

P592. A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab
Authors:

T. Wyant1, T. Leach1, S. Sankoh1, Y. Wang1, J. Paolino2, B. Feagan3, A. Parikh4, 1Millennium Pharmaceuticals, Inc., Cambridge, United States, 2University of Massachusetts Medical School, Worcester, United States, 3Robarts Research Institute, University of Western Ontario, London, Canada, 4Takeda Pharmaceuticals, Inc., Chicago, United States

P592

Comparative assessment of the safety of stem cells and standard anti-inflammatory therapy of Crohn's Disease

Authors:

O. Knyazev1, A. Kagramanova*1, A. Parfenov1, I. Ruchkina1, A. Konoplyannikov2, A. Churikova1

1Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation

P593.

The incidence and natural history of paediatric Inflammatory Bowel Disease Unclassified in Scotland

Authors:

F.L. Cameron1, P. Henderson1, R.K. Russell2, D.C. Wilson1, 1University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, 2Royal Hospital for Sick Children, Paediatric Gastroenterology, Glasgow, United Kingdom

P593. A patient's perspective on anaemia in inflammatory bowel disease
Authors:

C. Hoffman1, S. Vel1, M. Greco2, S. Danese2, H. Szabo2, B. Wilson2, L. Avedano2, 1Vifor Pharma Ltd, Glattbrugg, Switzerland, 2EFCCA, Brussels, Belgium

P593

Efficacy and safety of retreatment with vedolizumab in patients with Crohn's disease

Authors:

B.E. Sands*1, I. Shafran2, F.A. Farraye3, A.S. Cheifetz4, B. Abhyankar5, S. Sankoh6, M. Smyth7

1Icahn School of Medicine at Mount Sinai Hospital, Gastroenterology, New York, United States, 2Shafran Gastroenterology Center, Gastroenterology, Winter Park, FL, United States, 3Boston Medical Center, Gastroenterology, Boston, MA, United States, 4Beth Israel Deaconess Medical Center, Medicine, Boston, MA, United States, 5Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom, 6Takeda Pharmaceuticals International Co., Statistics, Cambridge, Massachusetts, United States, 7Takeda Global Research and Development Centre (Europe) Ltd., Medical, London, United Kingdom

P594.

The epidemiology of inflammatory bowel disease in children of Manitoba: 30 years' experience

Authors:

W. El-Matary1, S. Moroz1, C. Bernstein2, 1Faculty of Medicine, University of Manitoba, Pediatric Gastroenterology, Winnipeg, Canada, 2Faculty of Medicine, University of Manitoba, Gastroenterology, Winnipeg, Canada